The AZALEA–TIMI 71 trial compared abelacimab, a monoclonal antibody targeting factor XI, with rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk.
🚨 New study: Abelacimab vs. Rivaroxaban in AFib 📊
✅ 62-69% lower bleeding risk than rivaroxaban
✅ 5x lower GI bleeding
⚠️ Slightly higher ischemic stroke rates
A promising safer anticoagulant? 🔬 More data needed! #CardioTwitter #CardioEd #MedEd
Abelacimab significantly reduced bleeding compared to rivaroxaban (HR: 0.38 for 150 mg, 0.31 for 90 mg, p<0.001).
Gastrointestinal bleeding was five times lower with abelacimab. However, ischemic stroke rates were slightly higher.
The study highlights abelacimab's potential as a safer anticoagulant, with further phase 3 trials (LILAC–TIMI 76) needed to assess stroke prevention efficacy.
